ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0103

Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis

Félicie Costantino1, roula Said-Nahal2, Hendrick Mambu Mambueni3, Anne Boland4, Jean-François Deleuze4, Matthew Brown5, Henri-Jean Garchon3 and Maxime Breban6, 1Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR 1173, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, 2Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR 1173, Inserm, UVSQ/Université Paris Saclay, Boulogne-Billancourt, France, 3Infection & Inflammation, UMR 1173, Inserm, UVSQ/Université Paris Saclay, Montigny le Bretonneux, France, 4Centre National de Recherche en Génomique Humaine (CNRGH), Centre National de Recherche en Génomique Humaine (CNRGH), Université Paris-Saclay, CEA, Evry, France, 5Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, 6CHU Ambroise-Paré, Boulogne-Billancourt, France

Meeting: ACR Convergence 2025

Keywords: genetics, spondyloarthritis, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Spondyloarthritis (SpA) exhibits strong familial aggregation, with close relatives of patients having a significantly higher risk of developing the disease. This pattern might be driven by an accumulation of common variants that collectively increase disease risk or by rare variants in high linkage disequilibrium (LD) with common risk alleles, amplifying the genetic predisposition in affected families. Our aim was to investigate whether the familial form of SpA is influenced by an excess burden of common risk variants or by rare variants located within SpA-associated loci.

Methods: We examined two independent patient groups: (1) a family-based cohort of 376 SpA patients from 68 French families with at least four affected members, all of whom underwent whole genome sequencing (WGS), and (2) a cohort of 242 French unrelated ankylosing spondylitis (AS) patients with and without a family history of SpA, genotyped on the Illumina CoreExome array. Polygenic risk score (PRS) for AS were calculated using a model developed by Li et al. for Western European population (Li Z et al. doi: 10.1136/annrheumdis-2020-219446). Linear regression was applied to identify PRS-associated factors, and HLA-B27 frequency differences between sporadic and familial cases were analyzed using the chi-square test. We identified 46 coding genes overlapping with SNPs in high LD (r² >0.8) with lead SNPs from the 42 known AS-associated loci (Ellinghaus D et al. doi : 10.1038/ng.3528). To examine whether rare variants within these genes contribute to familial SpA, we conducted a rare variant burden test in our family cohort using gnomAD data as controls (Lali R et al. doi: 10.1038/s41467-021-26114-0).

Results: PRS was significantly increased in patients with familial history of SpA (68 probands from multiplex families and 123 patients from the unrelated cohort) compared to 119 sporadic cases (β-estimate (β)± standard error (SE): 0.09 ± 0.03; p-value (p) = 0.004; Figure 1A). However, the HLA-B27 positivity rate was significantly higher in familial cases compared to sporadic cases (94.2% vs 78.2%; p = 6×10-5) and the PRS difference was no longer significant when comparing only HLA-B27 positive patients (β ± SE: 0.003 ± 0.03; p = 0.9; figure 1B). Within the familial cohort, PRS was inversely associated with the number of affected family-members (β ± SE: -0.08 ± 0.03; p = 0.03). WGS data from the familial cohort revealed at least one non-synonymous SNPs with a minor allele frequency below 1% in non-Finnish European population and a predicted pathogenicity CADD score above 20 in 19 of the 46 AS-associated coding genes. The rare variant-burden test showed nominal association with familial SpA only for the PDE4A gene (p=0.05).

Conclusion: Besides the higher prevalence of HLA-B27, we found no significant accumulation of common AS-associated variants in familial cases of SpA. Furthermore, there was no excess of rare variants in genes within AS-associated loci, with the exception of a nominal association for PDE4A. Altogether these results suggest the involvement of other genetic factors, such as rare variants in additional genes, or environmental factors contributing to the strong familial aggregation of SpA.

Supporting image 1Figure 1 – Distribution of PRS according to family history status in all SpA patients (panel A) or in HLA-B27 positive patients only (panel B)


Disclosures: F. Costantino: AbbVie, 2, 6, Amgen, 2, 6, Celltrion, 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Novartis, 2, 6, UCB, 2, 6; r. Said-Nahal: None; H. Mambu Mambueni: None; A. Boland: None; J. Deleuze: None; M. Brown: Altis Medicines, 2, Clementia, 2, Grey Wolf, 2, Incyte, 2, Ipsen, 2, UCB, 5; H. Garchon: None; M. Breban: MSD, 5, Novartis, 2, 5, UCB, 2.

To cite this abstract in AMA style:

Costantino F, Said-Nahal r, Mambu Mambueni H, Boland A, Deleuze J, Brown M, Garchon H, Breban M. Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/common-and-rare-variant-contributions-to-familial-aggregation-in-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/common-and-rare-variant-contributions-to-familial-aggregation-in-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology